IRIS
MORE', Sonia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.592
AS - Asia 1.079
EU - Europa 772
SA - Sud America 329
AF - Africa 77
OC - Oceania 2
Totale 3.851
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.525
VN - Vietnam 303
BR - Brasile 260
SG - Singapore 257
IT - Italia 251
CN - Cina 188
RU - Federazione Russa 169
HK - Hong Kong 155
DE - Germania 77
FR - Francia 70
FI - Finlandia 51
IN - India 39
CI - Costa d'Avorio 35
AR - Argentina 33
BD - Bangladesh 32
GB - Regno Unito 30
MX - Messico 27
CA - Canada 26
NL - Olanda 25
IE - Irlanda 23
AT - Austria 18
JP - Giappone 15
MA - Marocco 12
IQ - Iraq 11
ZA - Sudafrica 11
ID - Indonesia 10
SE - Svezia 10
SA - Arabia Saudita 9
TR - Turchia 9
CO - Colombia 8
EC - Ecuador 8
PL - Polonia 8
UA - Ucraina 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
UZ - Uzbekistan 7
ES - Italia 6
PY - Paraguay 6
CR - Costa Rica 5
PK - Pakistan 5
KE - Kenya 4
KR - Corea 4
MY - Malesia 4
PE - Perù 4
SN - Senegal 4
TN - Tunisia 4
BE - Belgio 3
DK - Danimarca 3
HU - Ungheria 3
JO - Giordania 3
TH - Thailandia 3
TW - Taiwan 3
AU - Australia 2
BH - Bahrain 2
CH - Svizzera 2
DZ - Algeria 2
EG - Egitto 2
HN - Honduras 2
HR - Croazia 2
LT - Lituania 2
NP - Nepal 2
PH - Filippine 2
RO - Romania 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GR - Grecia 1
GT - Guatemala 1
IL - Israele 1
IS - Islanda 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MT - Malta 1
MU - Mauritius 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
UY - Uruguay 1
Totale 3.851
Salva come PNG Salva come JPEG
Città #
Ashburn 393
Dallas 373
Hong Kong 152
Singapore 152
San Jose 142
Ho Chi Minh City 110
Hanoi 61
Boardman 50
Council Bluffs 43
Los Angeles 41
Beijing 39
Munich 36
Abidjan 35
Helsinki 35
Lauterbourg 35
The Dalles 35
New York 28
São Paulo 28
Moscow 27
Dublin 23
Hefei 23
Chandler 22
Milan 21
Rome 21
Frankfurt am Main 18
Chicago 17
Da Nang 16
Denver 16
Buffalo 15
Santa Clara 15
Turku 15
Nuremberg 14
Orem 12
Mexico City 11
Montreal 11
Amsterdam 10
Ancona 10
Brooklyn 10
Chennai 10
Guangzhou 10
Haiphong 10
Tokyo 10
Biên Hòa 9
Turin 8
Warsaw 8
Bari 7
Bologna 7
Hải Dương 7
Johannesburg 7
Phoenix 7
Xi'an 7
Can Tho 6
Houston 6
Lawrence 6
Manchester 6
Princeton 6
Rio de Janeiro 6
Shenzhen 6
Tashkent 6
Atlanta 5
Baghdad 5
Boston 5
Curitiba 5
Fairfield 5
Falconara Marittima 5
Jiujiang 5
London 5
North Charleston 5
Poplar 5
Porto Alegre 5
Redmond 5
Salt Lake City 5
San Francisco 5
Seattle 5
Thái Nguyên 5
Belo Horizonte 4
Buenos Aires 4
Camden 4
Caracas 4
Dakar 4
Huế 4
Mumbai 4
New Delhi 4
Osimo 4
Pescara 4
Ribeirão Preto 4
Santo André 4
Toronto 4
Tunis 4
Vienna 4
Washington 4
Yiwu 4
Bogotá 3
Brasília 3
Brussels 3
Corridonia 3
Florence 3
Guarulhos 3
Holstebro 3
Lima 3
Totale 2.442
Salva come PNG Salva come JPEG
Nome #
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial 213
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 153
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 134
Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre 133
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 125
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study 123
Current Main Topics in Multiple Myeloma 123
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 122
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 120
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study 114
Developments in consolidation and maintenance strategies in post-remission multiple myeloma 110
Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia 110
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis 108
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety 107
Editorial: Reviews in hematologic malignancies 106
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma 106
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 105
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 101
AL amyloidosis: an overview on diagnosis, staging system, and treatment 99
A rare case of solitary plasmacytoma mimicking submucosal lesion of ascending colon: a case report and literature review 99
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy 97
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 97
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 96
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences 96
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 95
Long-Term Survival with Multiple Myeloma: An Italian Experience 95
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights 94
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy 94
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group 93
Monoclonal antibodies: Leading actors in the relapsed/refractory multiple myeloma treatment 83
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management 81
Plasma cell leukemia: first diagnostic approach in the laboratory|Leucemia plasmacellulare: primo inquadramento diagnostico in laboratorio 78
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments 72
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 68
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report 67
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients 62
Novel Experimental Drugs for Treatment of Multiple Myeloma 57
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience 53
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy 50
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice? 14
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy 11
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape 8
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application 6
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone 5
Totale 3.983
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.200
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.200
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202232 0 0 0 0 0 0 10 0 6 2 7 7
2022/202372 8 7 8 3 5 3 0 3 16 0 13 6
2023/2024190 22 3 7 5 22 6 3 6 8 8 26 74
2024/2025783 65 36 20 11 16 77 86 29 162 87 89 105
2025/20262.906 215 230 461 300 267 213 459 203 178 231 79 70
Totale 3.983